# Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

> **NCT01277757** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01277757
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01277757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01277757, "Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01277757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*